Patients report fewer postop halos after thermal pulsation treatment
Click Here to Manage Email Alerts
Treating patients with TearScience LipiFlow prior to cataract surgery resulted in a reduction of halos and an improvement in meibomian gland score, according to a study sponsored by Johnson & Johnson Vision.
The LipiFlow treatment applies heat and pressure to the eyelids to address evaporative dry eye or lipid deficiency dry eye caused by meibomian gland dysfunction, the company said.
In the prospective, multicenter clinical study, researchers examined the postoperative ocular symptoms of 115 patients who received treatment with LipiFlow, compared with patients who did not, according to the release.
In the LipiFlow group, 58.6% of patients reported halos, while 79% of patients without the treatment reported halos, the release said. Similarly, meibomian gland function in LipiFlow patients improved by 107%, but only 66% in patients who did not receive the treatment.
Researchers also saw improvements in postoperative anterior ocular health and visual acuity among the treated patients.
"We continue to learn more about the connection between the health of the ocular surface and visual outcomes following cataract surgery," Daniel Chang, MD, said in the release. "This new data reinforces the importance of proactively screening for and treating MGD prior to cataract surgery. It's a simple addition to the patient's treatment plan that may result in better visual outcomes for our patients."
Read more about
Click Here to Manage Email Alerts